Northwestern Medicine investigators have discovered that a subset of proteins in mitochondria of brain and heart cells are long-lived, supporting the long-term stability of mitochondrial complex architecture.
The study, published in the Journal of Cell Biology, was led by Jeffrey Savas, PhD, assistant professor in the Ken & Ruth Davee Department of Neurology’s Division of Behavioral Neurology, of Medicine the in Division of Nephrology and Hypertension, and of Pharmacology.
Previous work led by Savas discovered that nuclear pore complex proteins in post-mitotic neurons are exceptionally long-lived and persist for months in mouse and rat brains. These proteins, termed long-lived proteins, or LLPs, provide long-term stability and structure to the nuclear pore and subsequently to the nuclear envelope of neurons; however, this concept had never been considered for other intracellular organelles, until now.
Advancing the well-being of animals, people and the planet — aaron schacht — executive vice president, innovation, regulatory & business development, elanco.
Aaron Schacht is Executive Vice President: Innovation, Regulatory + Business Development at Elanco (https://www.elanco.com/), an American pharmaceutical company which produces medicines and vaccinations for pets and livestock, and which until 2,019 was a subsidiary of Eli Lilly and Company.
Prior to this, Mr. Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache.
In 2,012 Mr. Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry.
In 2,002 during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up.
Previously, Mr. Schacht held roles as Managing Director of Lilly University, Director of Knowledge Management, and Manager of Strategy and Productivity for Discovery Research.
Mr. Schacht began his career at Lilly in1990as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders.
Mr. Schacht studied Organic Chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Sharp wave-ripples from the hippocampus are shown to modulate peripheral glucose homeostasis in rats, offering insights into the mechanism that links sleep disruption and blood glucose regulation in type 2 diabetes.
Deploying two unrelated CRISPR nucleases in tandem, with multiplexed CRISPR RNAs and a chemically stabilized activator, creates a simple, one-step assay that can rapidly detect attomolar concentrations of RNA without needing target amplification.
Economists have learned that new technological breakthroughs usually don’t cause a jump in productivity right away. The technology needs time to marinate so companies can test how best to deploy it in their industry. Brynjolfsson argues artificial intelligence and machine learning have now simmered long enough to make a dramatic difference. Others are not as convinced.
Rapid adoption of robots and artificial intelligence during the pandemic combined with a rebound in government investment is making some economists optimistic about a return of a 1990s economy with widespread benefits.
Summary: Researchers discuss different current neural network models and consider the steps that need to be taken to make them more realistic, and thus more useful, as possible.
Source: University of Plymouth.
Neuroscience is a field most obviously associated with medicine and/or psychology. However, my background in physics and computer science enables me to explore, and further understand, how the brain computes and stores information, identifying the underlying physical mechanisms and the interplay between them.
As the disease swept the globe and scientists deployed tools such as polymerase chain reaction tests to detect the novel coronavirus in people, a team of researchers at the University of Pennsylvania’s School of Veterinary Medicine worked to determine if dogs could also be trained to find infections.
The proof-of-concept study, published in April in the journal PLOS ONE, showed that the virus has an odor that trained dogs can identify in urine and saliva. Now, the researchers—with the help of Tuuka, Griz, Toby, Rico, and Roxie—are examining whether canines can sniff out coronavirus’ scent in sweaty T-shirts.
If the dogs can accurately detect it on clothing, they could patrol places such as airports and stadiums to sniff out the virus in public settings.
SARS-CoV-2, the new coronavirus that causes COVID-19, is sensitive to high temperatures.
Research shows it can be quickly killed at 70°C (158°F). It’s possible that slightly lower temperatures may also be effective, but these require a longer exposure time.
Aside from laundry, there aren’t many temperature-related ways to safely and effectively kill the new coronavirus in your home. Additionally, some temperature-related methods can actually be harmful.
